1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.2.1. Research Assumptions
1.2.2. Project Methodology
1.2.3. Forecast Methodology
1.2.4. Robust Quality Control
1.2.5. Key Considerations
1.2.5.1. Demographics
1.2.5.2. Economic Factors
1.2.5.3. Government Regulations
1.2.5.4. Supply Chain
1.2.5.5. COVID Impact / Related Factors
1.2.5.6. Market Access
1.2.5.7. Healthcare Policies
1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines
3. INTRODUCTION
3 Introduction
3.1. Chapter Overview
3.2. Overview of Biologics
3.2.1. Types of Biologics
3.3. Overview of Contract Research Organizations (CROs)
3.4. Evolution of CROs
3.5. Classification of CROs
3.6. Services Offered by CROs
3.7. Advantages of Outsourcing Operations to CROs
3.8. Risks Associated with Outsourcing Operations to CROs
4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Biologics Research
4.3. Models of Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Model
4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach
4.5. Selecting a CRO Partner
4.5.1. Key Considerations for Outsourcing Biologics-related Operations
4.6. Role of CROs in the Drug Development Process
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services
4.7. Conclusion
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Biopharmaceutical CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
5.2.2. Analysis by Scale of Operation
5.3. Preclinical Biopharmaceutical CROs
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Biologic
5.3.5. Analysis by Type of Services Offered
5.4. Clinical Biopharmaceutical CROs
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Analysis by Type of Biologics
5.4.5. Analysis by Type of Services Offered
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Biocon
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Services Portfolio
6.2.4. Future Outlook
6.3. Covance
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Financial Information
6.3.4. Future Outlook
6.4. ICON
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Future Outlook
6.5. Medpace
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Future Outlook
6.6. Pharmaron
6.6.1. Company Overview
6.6.2. Services Portfolio
6.6.3. Future Outlook
6.7. PPD
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Financial Information
6.7.4. Future Outlook
6.8. PRA Health Sciences
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Service Portfolio
6.8.4. Future Outlook
6.9. Syneos Health
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Services Portfolio
6.9.4. Future Outlook
6.10. Vimta Labs
6.10.1. Company Overview
6.10.2. Services Portfolio
6.10.3. Financial Information
6.10.4. Future Outlook
6.11. WuXi AppTec
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Service Portfolio
6.11.4. Future Outlook
7. BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Peer Group I
7.3.2. Peer Group II
7.3.3. Peer Group III
7.3.4. Peer Group IV
7.3.5. Peer Group V
7.3.6. Peer Group VI
7.3.7. Peer Group VII
7.3.8. Peer Group VIII
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Biopharmaceutical CROs: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership Model
8.3.2.1. Analysis by Year of Partnership and Type of Partnership Model
8.3.3. Most Active Players: Analysis by Number of Partnerships
8.3.4. Analysis by Scale of Operation
8.3.5. Analysis by Geography
8.3.5.1. Country-wise Analysis
8.3.5.2. Intercontinental and Intracontinental Agreements
9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Biopharmaceutical CROs: Mergers and Acquisitions
9.3.1. Analysis by Year of Acquisition
9.3.2. Analysis by Type of Collaboration
9.3.3. Analysis by Geography
9.3.3.1. Continent-wise Distribution
9.3.3.2. Country-wise Distribution
9.3.4. Ownership Change Matrix
9.3.5. Most Active Acquirers: Analysis by Number of Acquisitions
9.4. Distribution by Key Value Drivers
9.4.1. Analysis by Key Value Drivers
9.4.2. Analysis by Key Value Drivers and Year of Acquisitions
9.5. Valuation Analysis: Acquisition Deal Multiples
10. ATTRACTIVENESS COMPETITIVENESS MATRIX
10.1. Chapter Overview
10.2. AC Matrix: Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment
10.3. Analytical Methodology
10.4. AC Matrix: Contract Manufacturing Scenario in North America
10.5. AC Matrix: Contract Manufacturing Scenario in Europe
10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Biopharmaceutical CROs Market
11.3.1. Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
11.3.2. Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
11.3.3. Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
11.3.4. Global Biopharmaceutical CROs Market: Distribution by Geography
11.4. Biopharmaceutical CROs Market in North America
11.4.1. Biopharmaceutical CROs Market in North America: Distribution by Therapeutic Area
11.4.1.1. Biopharmaceutical CROs Market for Oncological Disorders in North America, Till 2035
11.4.1.2. Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Till 2035
11.4.1.3. Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Till 2035
11.4.1.4. Biopharmaceutical CROs Market for Neurological Disorders in North America, Till 2035
11.4.1.5. Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Till 2035
11.4.2. Biopharmaceutical CROs Market in North America: Distribution by Scale of Operation
11.4.2.1. Biopharmaceutical CROs Market for Preclinical Operations in North America, Till 2035
11.4.2.2. Biopharmaceutical CROs Market for Clinical Operations in North America, Till 2035
11.5. Biopharmaceutical CRO Services Market in Europe
11.5.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Europe
11.5.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Europe, Till 2035
11.5.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Europe, Till 2035
11.5.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Europe, Till 2035
11.5.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Europe, Till 2035
11.5.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Europe, Till 2035
11.5.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Europe
11.5.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Europe, Till 2035
11.5.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Europe, Till 2035
11.6. Biopharmaceutical CRO Services Market in Asia-Pacific
11.6.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Asia-Pacific
11.6.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Asia-Pacific, Till 2035
11.6.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Asia-Pacific, Till 2035
11.6.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Asia-Pacific, Till 2035
11.6.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Asia-Pacific, Till 2035
11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Asia-Pacific, Till 2035
11.6.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Asia-Pacific
11.6.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Asia-Pacific, Till 2035
11.6.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Asia-Pacific, Till 2035
11.7. Biopharmaceutical CRO Services Market in Latin America
11.8. Biopharmaceutical CRO Services Market in Middle East North America
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors
LIST OF FIGURES
Figure 3.1 Types of Biologics
Figure 3.2 Stages of the Drug Development Process
Figure 3.3 Commonly Offered Services by CROs
Figure 3.4 Advantages of Outsourcing Operations to CROs
Figure 3.5 Risks Associated with Outsourcing Operations to CROs
Figure 4.1 Guiding Models for Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance / Outcome based Business Model
Figure 4.4 Steps to Consider before Outsourcing
Figure 4.5 Key Considerations while Selecting a CRO Partner
Figure 4.6 Role of CROs in the Drug Development Process
Figure 5.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Figure 5.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Figure 5.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Figure 5.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Figure 5.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Figure 5.7 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Figure 5.8 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Figure 5.9 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 5.10 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Figure 5.11 Biopharmaceutical Clinical CROs: Distribution by Company Size
Figure 5.12 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Figure 5.13 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Figure 5.14 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Figure 5.15 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Figure 5.16 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 6.1 Biocon: Annual Services Revenues, Since 2016 (INR Billion)
Figure 6.2 Biocon: Service Portfolio
Figure 6.3 Covance: Annual Services Revenues, Since 2016 (USD Billion)
Figure 6.4 Covance: Service Portfolio
Figure 6.5 ICON: Annual Revenues, Since 2016 (USD Billion)
Figure 6.6 ICON: Service Portfolio
Figure 6.7 Medpace: Annual Services Revenues, Since 2016 (USD Billion)
Figure 6.8 Medpace: Service Portfolio
Figure 6.9 Medpace: Regulatory Affair Capabilities
Figure 6.10 Pharmaron: Service Portfolio
Figure 6.11 PPD: Annual Services Revenues, Since 2016 (USD Billion)
Figure 6.12 PPD: Service Portfolio
Figure 6.13 PRA Health Sciences: Annual Revenues, Since 2016 (USD Billion)
Figure 6.14 PRA Health Sciences: Service Portfolio
Figure 6.15 Syneos Health: Annual Services Revenues, Since 2016 (USD Billion)
Figure 6.16 Syneos Health: Service Portfolio
Figure 6.17 Vimta Labs: Annual Service Revenues, Since 2016 (INR Billion)
Figure 6.18 Vimta Labs: Service Portfolio
Figure 6.19 WuXi App Tec: Annual Services Revenues, Since 2016 (USD Billion)
Figure 6.20 WuXi App Tec: Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution by Company Size and Location of Headquarters
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 7.7 Benchmark Analysis: Peer Group VI
Figure 7.8 Benchmark Analysis: Peer Group VII
Figure 7.9 Benchmark Analysis: Peer Group VIII
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership Model
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
Figure 8.4 Most Active Players: Distribution by Number of Partnerships
Figure 8.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 8.6 Partnerships and Collaborations: Distribution by Geography
Figure 8.7 Partnerships and Collaborations: Country-Wise Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (Since 2016)
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Figure 9.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
Figure 9.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 9.5 Mergers and Acquisitions: Region-wise Distribution
Figure 9.6 Mergers and Acquisitions: Country-wise Distribution
Figure 9.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 9.8 Mergers and Acquisitions: Key Value Drivers
Figure 9.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 9.10 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 9.11 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Figure 10.1. AC Matrix: Pictorial Representation
Figure 10.2. AC Matrix: Positioning of Different Biologics in North America
Figure 10.3. AC Matrix: Positioning of Different Biologics in Europe
Figure 10.4. AC Matrix: Positioning of Different Biologics in Asia Pacific
Figure 11.1 Biopharmaceutical CROs: Market Forecast Methodology
Figure 11.2 Global Biopharmaceutical CROs Market, Till 2035
Figure 11.3 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
Figure 11.4 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
Figure 11.5 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
Figure 11.6 Global Biopharmaceutical CROs Market: Distribution by Geography
Figure 11.7 Biopharmaceutical CROs Market in North America, Till 2035 (USD Million)
Figure 11.8 Biopharmaceutical CROs Market for Oncological Disorders in North America, Till 2035 (USD Million)
Figure 11.9 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Till 2035 (USD Million)
Figure 11.10 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Till 2035 (USD Million)
Figure 11.11 Biopharmaceutical CROs Market for Neurological Disorders in North America, Till 2035 (USD Million)
Figure 11.12 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Till 2035 (USD Million)
Figure 11.13 Biopharmaceutical CROs Market for Preclinical Operations in North America, Till 2035 (USD Million)
Figure 11.14 Biopharmaceutical CROs Market for Clinical Operations in North America, Till 2035 (USD Million
Figure 11.15 Biopharmaceutical CROs Market in Europe, Till 2035 (USD Million)
Figure 11.16 Biopharmaceutical CROs Market for Oncological Disorders in Europe, Till 2035 (USD Million)
Figure 11.17 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, Till 2035 (USD Million)
Figure 11.18 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, Till 2035 (USD Million)
Figure 11.19 Biopharmaceutical CROs Market for Neurological Disorders in Europe, Till 2035 (USD Million)
Figure 11.20 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, Till 2035 (USD Million)
Figure 11.21 Biopharmaceutical CROs Market for Preclinical Operations in Europe, Till 2035 (USD Million)
Figure 11.22 Biopharmaceutical CROs Market for Clinical Operations in Europe, Till 2035 (USD Million)
Figure 11.23 Biopharmaceutical CROs Market in Asia-Pacific, Till 2035 (USD Million)
Figure 11.24 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, Till 2035 (USD Million)
Figure 11.25 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, Till 2035 (USD Million)
Figure 11.26 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, Till 2035 (USD Million)
Figure 11.27 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, Till 2035 (USD Million)
Figure 11.28 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, Till 2035 (USD Million)
Figure 11.29 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, Till 2035 (USD Million)
Figure 11.30 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, Till 2035 (USD Million)
Figure 11.31 Biopharmaceutical CROs Market in Latin America, Till 2035 (USD Million)
Figure 11.32 Biopharmaceutical CROs Market in Middle East North Africa, Till 2035 (USD Million)
Figure 11.33 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.1 Biopharmaceutical CROs SWOT Analysis: Overview
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1 Concluding Remarks: Current Market Landscape for Preclinical Biopharmaceutical CROs
Figure 13.2 Concluding Remarks: Current Market Landscape for Clinical Biopharmaceutical CROs
Figure 13.3 Concluding Remarks: Recent Partnerships
Figure 13.4 Concluding Remarks: Mergers and Acquisitions
Figure 13.5 Concluding Remarks: Clinical Trial Analysis
Figure 13.6 Concluding Remarks: Market Sizing and Opportunity Analysis
LIST OF TABLES
Table 4.1 Attributes of Transactional Outsourcing Based Business Model
Table 4.2 Comparison of Key Factors Considered by Biologic Developers for Selecting a CRO Partner: Harvey Ball Analysis
Table 5.1 Biopharmaceutical CROs: Information on Year of Establishment, Location of Headquarters, Company Size and Types of Biologics
Table 5.2 Biopharmaceutical Preclinical CROs: Information on Types of Services Offered
Table 5.3 Biopharmaceutical Clinical CROs: Information on Types of Services Offered
Table 6.1 Biocon: Company Overview
Table 6.2 Biocon: Future Outlook
Table 6.3 Covance: Company Overview
Table 6.4 Covance: Future Outlook
Table 6.5 ICON: Company Overview
Table 6.6 ICON: Future Outlook
Table 6.7 Medpace: Company Overview
Table 6.8 Medpace: Future Outlook
Table 6.9 Pharmaron: Company Overview
Table 6.10 Pharmaron: Future Outlook
Table 6.11 PPD: Company Overview
Table 6.12 PPD: Future Outlook
Table 6.13 PRA Health Sciences: Company Overview
Table 6.14 PRA Health Sciences: Future Outlook
Table 6.15 Syneos Health: Company Overview
Table 6.16 Syneos Health: Future Outlook
Table 6.17 VIMTA Labs: Company Overview
Table 6.18 WuXi App-Tec: Company Overview
Table 6.19 WuXi App Tec: Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 Partnerships and Collaborations: List of Agreements, Since 2016
Table 9.1 Mergers and Acquisitions: List of Mergers / Acquisitions, Since 2016
Table 9.2 Mergers and Acquisitions: Information on Key Value Drivers, Since 2016
Table 9.3 Mergers and Acquisitions: Deal Multiples, Since 2016
Table 15.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 15.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Table 15.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Table 15.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Table 15.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Table 15.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Table 15.8 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Table 15.9 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Table 15.10 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types Services Offered
Table 15.11 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Table 15.12 Biopharmaceutical Clinical CROs: Distribution by Company Size
Table 15.13 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Table 15.14 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Table 15.15 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Table 15.16 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Table 15.17 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Table 15.18 Biocon: Annual Service Revenues, Since 2016 (INR Billion)
Table 15.19 Covance: Annual Service Revenues, Since 2016 (USD Billion)
Table 15.20 ICON: Annual Revenues, Since 2016 (USD Billion)
Table 15.21 Medpace: Annual Service Revenues, Since 2016 (USD Billion)
Table 15.22 PPD: Annual Service Revenues, Since 2016 (USD Billion)
Table 15.23 PRA Health Sciences: Annual Revenues, Since 2016 (USD Billion)
Table 15.24 Syneos: Annual Service Revenues, Since 2016 (USD Billion)
Table 15.25 Vimta Labs: Annual Service Revenues, Since 2016 (INR Billion)
Table 15.26 WuXi AppTec: Annual Service Revenues, Since 2016 (USD Billion)
Table 15.27 Partnerships and Collaborations: Distribution by Year of Partnership
Table 15.28 Partnerships and Collaborations: Distribution by Type of Partnership Model
Table 15.29 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
Table 15.30 Most Active Players: Distribution by Number of Partnerships
Table 15.31 Partnerships and Collaborations: Distribution by Scale of Operation
Table 15.32 Partnerships and Collaborations: Distribution by Geography
Table 15.33 Partnerships and Collaborations: Country-Wise Distribution
Table 15.34 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.35 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (Since 2016)
Table 15.36 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Table 15.37 Mergers and Acquisitions: Distribution by Year and Type of Agreement
Table 15.38 Mergers and Acquisitions: Continent-wise Distribution
Table 15.39 Mergers and Acquisitions: Continent-wise Distribution
Table 15.40 Mergers and Acquisitions: Country-wise Distribution
Table 15.41 Mergers and Acquisitions: Ownership Change Matrix
Table 15.42 Mergers and Acquisitions: Key Value Drivers
Table 15.43 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 15.44 Mergers and Acquisitions: Deal Multiples Based on Revenue
Table 15.45 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Table 15.46 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
Table 15.47 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
Table 15.48 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
Table 15.49 Global Biopharmaceutical CROs Market: Distribution by Geography
Table 15.50 Biopharmaceutical CROs Market in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.51 Biopharmaceutical CROs Market for Oncological Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.52 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.53 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.54 Biopharmaceutical CROs Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.55 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.56 Biopharmaceutical CROs Market for Preclinical Operations in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.57 Biopharmaceutical CROs Market for Clinical Operations in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.58 Biopharmaceutical CROs Market in Europe, Till 2035 (USD Million)
Table 15.59 Biopharmaceutical CROs Market for Oncological Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.60 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, Till 2035 (USD Million)
Table 15.61 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.62 Biopharmaceutical CROs Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.63 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.64 Biopharmaceutical CROs Market for Preclinical Operations in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.65 Biopharmaceutical CROs Market for Clinical Operations in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.66 Biopharmaceutical CROs Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.67 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.68 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.69 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.70 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.71 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.72 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.73 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.74 Biopharmaceutical CROs Market for Preclinical Operations in Latin America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.75 Biopharmaceutical CROs Market for Preclinical Operations in Middle East North Africa, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 15.76 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios (USD Million)
